Market Newsdesk

LOUISVILLE, Ky., Aug. 28, 2025 (GLOBE NEWSWIRE) — Stock Yards Bancorp, Inc. (NASDAQ: SYBT), parent company of Stock Yards Bank & Trust Company, with offices in Louisville, central, eastern and northern Kentucky, as well as the Indianapolis, Indiana and Cincinnati, Ohio metropolitan markets, today announced that Ja Hillebrand, Chairman and CEO and T. Clay Stinnett, EVP and CFO will participate in the Raymond James 2025 U.S. Bank and Banking on Tech Conferences to be held September 3^rd through September 4^th, and will participate in a series of one-on-one meetings with institutional investors.

Management’s discussion materials to be used at this conference will be posted to the investor section of the Company’s website, www.syb.com, on or before September 3, 2025.

Louisville, Kentucky-based Stock Yards Bancorp, Inc., with $9.21 billion in assets, was incorporated in 1988 as a bank holding company. It is the parent company of Stock Yards Bank & Trust Company, which was established in 1904. The Company’s common shares trade on The Nasdaq Stock Market under the symbol “SYBT.”

Contact:	T. Clay Stinnett
	Executive Vice President,
	Treasurer and Chief Financial Officer
	(502) 625-0890

WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows:

Cantor Global Healthcare Conference

Thursday, September 4, 2025, at 2:45pm ET

H.C. Wainwright 27th Annual Global Investment Conference

Monday, September 8, 2025, at 10:30am ET

A live webcast of both presentations will be available on the Events and Presentations section of Palvella’s website at www.palvellatx.com. An archived replay of the webcast will be available for approximately 90 days following the presentation.

About Palvella Therapeutics

Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being evaluated in the Phase 3 SELVA clinical trial in microcystic lymphatic malformations and the Phase 2 TOIVA clinical trial in cutaneous venous malformations. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter). QTORIN™ rapamycin is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency for any indication.

Contact Information

Investors

Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
[email protected]

Media

Marcy Nanus
Managing Partner, Trilon Advisors, LLC
[email protected]

WALTHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) — Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in September:

• Cantor Global Healthcare Conference 2025, fireside chat on Thursday, September 4, 2025, at 1:00 p.m. ET in New York.

• Morgan Stanley 23
  
  ^rd
  
  Annual Global Healthcare Conference, fireside chat on Monday, September 8, 2025, at 5:35 p.m. ET in New York.

A live webcast of each presentation will be available in the Investors section of the Company’s website at https://investors.crescentbiopharma.com/news-events/events, and a replay will be accessible for 90 days.

About Crescent Biopharma

Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.

Contact

Amy Reilly
Chief Communications Officer
[email protected]
617-465-0586

CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced four posters on MIPLYFFA^® (MY-PLY-FAH) (arimoclomol) will be presented at the International Congress of Inborn Errors of Metabolism (ICIEM), taking place September 2-6, 2025, in Kyoto, Japan.

MIPLYFFA is approved in the U.S. for the treatment of Niemann-Pick disease type C (NPC). A poster (# BP-19) detailing that MIPLYFFA’s mechanism of action uniquely targets the underlying pathophysiology of NPC was selected for a Best Poster award. Additionally, positive, new data from a multi-center pediatric substudy in patients younger than two years old, as well as a new prespecified efficacy analysis of patients on routine clinical care with miglustat who switched from placebo to MIPLYFFA in their treatment regimen, will be presented.

Poster Details

Title:	Safety and efficacy of arimoclomol in a pediatric substudy of Niemann-Pick disease type C patients aged 6 to <24 months at study enrollment
Presentation No:	P-261
Date/Time:	Wednesday, September 3, 2025; 6:00pm JST
Presenter:	Laila Arash-Kaps, M.D.; SpinCS, Clinical Science for LSD

Title:	Arimoclomol upregulates expression of genes belonging to the coordinated lysosomal expression and regulation (CLEAR) network Best Poster Award
Presentation No:	BP-19
Date/Time:	Thursday, September 4, 2025; 5:30pm JST
Presenter:	Hadeel Shammas, Ph.D.; Zevra Therapeutics

Title:	Arimoclomol for the treatment of Niemann-Pick disease type C in a real-world setting: long-term outcomes from an expanded access program in the United States
Presentation No:	P-76
Date/Time:	Thursday, September 4, 2025; 5:30pm JST
Presenter:	Caroline Hastings, M.D.; UCSF Benioff Children’s Hospitals

Title:	Efficacy results across a 12-month double-blind randomized trial and an open-label extension phase of arimoclomol for treatment of Niemann-Pick disease type C in patients treated with miglustat
Presentation No:	P-264
Date/Time:	Thursday, September 4, 2025; 5:30pm JST
Presenter:	Laila Arash-Kaps, M.D.; SpinCS, Clinical Science for LSD

About MIPLYFFA^® (arimoclomol)

MIPLYFFA (arimoclomol) is Zevra’s approved therapy for the treatment of Niemann-Pick disease type C (NPC). Approved by the U.S. Food and Drug Administration on Sep. 20, 2024, MIPLYFFA (arimoclomol) increases the activation of the transcription factors EB (TFEB) and E3 (TFE3) resulting in the upregulation of coordinated lysosomal expression and regulation (CLEAR) genes. MIPLYFFA has also been shown to reduce unesterified cholesterol in the lysosomes of human NPC fibroblasts. The clinical significance of these findings is not fully understood. In the pivotal phase 3 trial, MIPLYFFA halted disease progression compared to placebo over the one-year duration of the trial when measured by the only validated disease progression measurement tool, the NPC Clinical Severity Scale. MIPLYFFA has also received Orphan Medicinal Product designation by the European Medicines Agency (EMA) for the treatment of NPC. The extensive data generated for MIPLYFFA has shown long-term, meaningful clinical outcomes with 5 and in some patients 7 years of patient experience across more than 270 NPC patients worldwide through a Phase 2/3 clinical trial, Open-Label Extension (OLE) study, Expanded Access Programs (EAP), and a pediatric sub-study, which is the most expansive clinical development program in NPC to date. A Marketing Authorization Application for the evaluation of arimoclomol for the treatment of Niemann-Pick disease type C has been validated and is under review by the European Medicines Agency. 

INDICATIONS AND USAGE

MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. 

IMPORTANT SAFETY INFORMATION 

Hypersensitivity Reactions:

Hypersensitivity reactions such as urticaria and angioedema have been reported in patients treated with MIPLYFFA during Trial 1: two patients reported both urticaria and angioedema (6%) and one patient (3%) experienced urticaria alone within the first two months of treatment. Discontinue MIPLYFFA in patients who develop severe hypersensitivity reactions. If a mild or moderate hypersensitivity reaction occurs, stop MIPLYFFA and treat promptly. Monitor the patient until signs and symptoms resolve.

Embryofetal Toxicity:

MIPLYFFA may cause embryofetal harm when administered during pregnancy based on findings from animal reproduction studies. Advise pregnant females of the potential risk to the fetus and consider pregnancy planning and prevention for females of reproductive potential. 

Increased Creatinine without Affecting Glomerular Function:

Across clinical trials of MIPLYFFA, mean increases in serum creatinine of 10% to 20% compared to baseline were reported. These increases occurred mostly in the first month of MIPLYFFA treatment and were not associated with changes in glomerular function.

During MIPLYFFA treatment, use alternative measures that are not based on creatinine to assess renal function. Increases in creatinine reversed upon MIPLYFFA discontinuation. 

The most common adverse reactions in Trial 1 (≥15%) in MIPLYFFA-treated patients who also received miglustat were upper respiratory tract infection, diarrhea, and decreased weight.
Three (6%) of the MIPLYFFA-treated patients had the following adverse reactions that led to withdrawal from Trial 1: increased serum creatinine (one patient), and progressive urticaria and angioedema (two patients). Serious adverse reactions reported in MIPLYFFA-treated patients were hypersensitivity reactions including urticaria and angioedema. 

To report SUSPECTED ADVERSE REACTIONS, contact Zevra Therapeutics, Inc. at toll-free phone 1-844-600-2237 or FDA at 1 800-FDA-1088 or www.fda.gov/medwatch.

Drug Interaction(s):

Arimoclomol is an inhibitor of the organic cationic transporter 2 (OCT2) transporter and may increase the exposure of drugs that are OCT2 substrates. When MIPLYFFA is used concomitantly with OCT2 substrates, monitor for adverse reactions and reduce the dosage of the OCT2 substrate.

Use in Females and Males of Reproductive Potential:

Based on animal findings, MIPLYFFA may impair fertility and may increase post-implantation loss and reduce maternal, placental, and fetal weights.

Renal Impairment:

The recommended dosage of MIPLYFFA, in combination with miglustat, in patients with an eGFR ≥15 mL/minute to <50 mL/minute is lower than the recommended dosage (less frequent dosing) in patients with normal renal function.

MIPLYFFA capsules for oral use are available in the following strengths: 47 mg, 62 mg, 93 mg, and 124 mg.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company combining science, data and patient need to create transformational therapies for rare diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Caution Concerning Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the promise and potential impact of our preclinical or clinical trial data; or the potential benefits of any of our products or product candidates for any specific disease or at any dosage. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on March 12, 2025, and Zevra’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed on August 12, 2025, and Zevra’s other filings with the SEC. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.  

Zevra Contact

Nichol Ochsner 
+1 (732) 754-2545 
[email protected]  

Store Openings, Sales, and Earnings Ahead of Expectations

Net Sales Increased 17.5% and Earnings Per Share Increased 25.0%

Raising Fiscal 2025 Sales and Earnings Outlook

HARRISBURG, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) —  Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today announced financial results for the second quarter fiscal 2025 ended August 2, 2025.

“We had a very strong second quarter and are operating with the wind in our sails,” said Eric van der Valk, President and Chief Executive Officer. “We are driving the business to new heights through improved planning, coordination, and execution across the organization. New store openings, total sales, comparable store sales, and earnings were all ahead of our expectations in the quarter and we are raising our full-year outlook across the board.”

Mr. van der Valk continued, “Consumers responded to our compelling assortment of bargains, especially in our consumer staples and seasonal categories. Ollie’s Army growth was another bright spot in the quarter, headlined by an outstanding response to our reimagined Ollie’s Days event.”

		Thirteen weeks ended
		August 2,				August 3,
			2025				2024
(Dollars in thousands, except per share data)
Net sales		$	679,556			$	578,375
Yr/yr change			17.5%				12.4%
Comparable store sales change(1)			5.0%				5.8%
Net income		$	61,310			$	48,982
Net income per diluted share		$	0.99			$	0.79
Adjusted net income per diluted share		$	0.99			$	0.78
Yr/yr change			26.9%				16.4%
Adjusted EBITDA		$	93,786			$	74,450
% of net sales			13.8%				12.9%
Store openings			29				9
Store growth, yr/yr change			16.8%				8.9%
(1)Calculated based on the comparable number of weeks from the prior year.

Second Quarter Fiscal 2025 Highlights and Year-Over-Year Comparisons     

• Opened 29 stores, ending the quarter with a total of 613 stores in 34 states, an increase of 16.8% year-over-year.
• Ollie’s Army loyalty members increased 10.6% to 16.1 million members.
• Net sales increased 17.5% to $679.6 million, driven by new store unit growth and an increase in comparable store sales.
• Comparable store sales increased 5.0%, driven by an increase in transactions.
• Gross margin increased 200 basis points to 39.9%. The increase was primarily driven by lower supply chain costs and higher merchandise margin.
• Selling, general, and administrative (“SG&A”) expenses as a percentage of net sales increased 60 basis points to 25.8%. The increase was primarily driven by higher medical and casualty claims, as well as slightly higher store labor expenses.
• Pre-opening expenses increased $4.4 million to $9.0 million, driven by new store growth and $2.3 million of dark rent expense associated with the former Big Lots locations that were acquired through the bankruptcy auction process.
• Operating margin increased 80 basis points to 11.3%.
• Adjusted net income per diluted share increased 26.9% to $0.99.
• Adjusted EBITDA increased 26.0% to $93.8 million and adjusted EBITDA margin increased 90 basis points to 13.8%.
• Total cash and investments increased 30.3%, or $107.1 million, to $460.3 million. This included cash and cash equivalents of $231.2 million, short-term investments of $85.9 million, and long-term investments of $143.2 million.  

Fiscal 2025 Outlook   

The Company is raising its previously provided sales and earnings outlook for fiscal 2025. A comparison of the current and previous outlook figures is contained in the table below.

	Current			Previous
Store Openings	85			75
Net sales	$2.631 to $2.644 billion			$2.579 to $2.599 billion
Comparable store sales increase	3.0% to 3.5%			1.4% to 2.2%
Gross margin	40.3%			40.0%
Operating income(1)	$292 to $298 million			$283 to $292 million
Adjusted net income (1)(2)(3)	$233 to $237 million			$225 to $232 million
Adjusted net income per diluted share(1)(2)(3)	$3.76 to $3.84			$3.65 to $3.75
Annual effective tax rate(3)	~ 25%			~ 25%
Diluted weighted average shares outstanding	~ 62 million			~ 62 million
Capital expenditures	$83 to $88 million			$83 to $88 million
(1) Includes dark rent expenses of approximately $5 million, or $0.06 in adjusted net income per diluted share, related to the opening of stores where the leases were acquired through the bankruptcy process.
(2) Includes interest income of approximately $18 million. This assumes the potential for lower interest rates in fiscal 2025.
(3) Excludes the excess tax benefits related to stock-based compensation, as the Company cannot predict such estimates without unreasonable effort.

Conference Call Information

A conference call to discuss second quarter fiscal 2025 financial results is scheduled for today, August 28, 2025, at 8:30 a.m. Eastern Time. To access the live conference call, please preregister here. Registrants will receive a confirmation with dial-in instructions. Interested parties can also listen to a live webcast or replay of the conference call by logging on to the Investor Relations section on the Company’s website at https://investors.ollies.com/. A replay of the conference call webcast will be available on the investor relations website for one year.

About Ollie’s        
Ollie’s is a leading off-price retailer of brand name household products. Since our founding in 1982, our mission has been to sell Good Stuff Cheap®. We do this through a flexible buying model that focuses on closeout merchandise and excess inventory from suppliers and manufacturers around the world. Our stores offer Real Brands! Real Bargains! ® in a treasure hunt environment at prices up to 70% below traditional retailers. As of August 2, 2025, we operated 613 stores in 34 states and growing! For more information, visit www.ollies.com.

Non-GAAP Reconciliation

The Company’s results are reported in this press release on a GAAP and as adjusted, non-GAAP basis. Adjusted net income (loss), adjusted net income (loss) per diluted share, and adjusted operating income (loss) are non-GAAP measures, and are not intended to replace GAAP financial information, and may be different from non-GAAP measures reported by other companies. The Company believes the income and expense items excluded as non-GAAP adjustments are not reflective of the performance of its core business, and that providing this supplemental disclosure to investors will facilitate comparisons of the past and present performance of its core business.

Please refer to the “Reconciliation of GAAP to Non-GAAP Financial Measures” table included in this press release, which sets forth the non-GAAP operating adjustments for the 13-week and 26-week periods ended August 2, 2025 and August 3, 2024.

Forward-Looking Statements

This press release contains certain forward-looking statements, which includes but is not limited to statements regarding industry trends, value creation, customer trends, new stores, distribution centers, and various financial outlook figures, including new store openings, net sales, comparable store sales, gross margin, SG&A, operating income, net income, adjusted net income, adjusted net income per diluted share, effective tax rate, diluted weighted average shares outstanding and capital expenditures. All forward-looking statements are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, are subject to the finalization of the Company’s quarterly financial and accounting procedures, and may be affected by certain risks and uncertainties, any one, or a combination, of which could materially affect the results of the Company’s operations. Forward-looking statements are usually identified by or are associated with such words as “could”, “may”, “might”, “will,” “likely”, “anticipates”, “intends”, “plans”, “believes”, “estimates”, “expects”, “continues”, “projects”, “forecasts”, and similar terminology. Actual results could vary materially from the expectations reflected in these statements. As with any business, all phases of our operations are subject to factors outside of our control. These factors include, without limitation, the impact of the recent tariff announcements and the corresponding macroeconomic pressures and those factors discussed in the “Risk Factors” section of the Company’s Annual Reports or Form 10-K and other filings with the Securities and Exchange Commission. Forward-looking statements made by or on behalf of the Company are based on knowledge of its business and the environment in which it operates, but because of the factors listed above, actual results could differ materially from those reflected by any forward-looking statements. Consequently, all of the forward-looking statements made are qualified by these cautionary statements and those contained in the Company’s Annual Report on Form 10-K, quarterly reports on Form 10-Q, and other filings with the Securities and Exchange Commission. There can be no assurance that the results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business and operations. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

Investor Contact

John Rouleau
Managing Director of Corporate Communication & Business Development
[email protected]

Media Contact

Tom Kuypers
Senior Vice President – Marketing & Advertising
717-657-2300
[email protected]

Ollie’s Bargain Outlet Holdings, Inc.

Condensed Consolidated Statements of Income (unaudited)

(In thousands except for per share amounts)

		Thirteen weeks ended								Twenty-six weeks ended
		August 2,				August 3,				August 2,				August 3,
			2025				2024				2025				2024
Net sales		$	679,556			$	578,375			$	1,256,323			$	1,087,193
Cost of sales			408,218				359,344				747,954				658,804
Gross profit			271,338				219,031				508,369				428,389
Selling, general and administrative expenses			175,476				145,673				340,308				288,092
Depreciation and amortization expenses			9,916				8,004				19,273				15,720
Pre-opening expenses			8,972				4,595				15,628				7,321
Operating income			76,974				60,759				133,160				117,256
Interest income, net			(4,534	)			(3,928	)			(9,322	)			(8,229	)
Income before income taxes			81,508				64,687				142,482				125,485
Income tax expense			20,198				15,705				33,612				30,161
Net income		$	61,310			$	48,982			$	108,870			$	95,324
Earnings per common share:
Basic		$	1.00			$	0.80			$	1.77			$	1.55
Diluted		$	0.99			$	0.79			$	1.76			$	1.54
Weighted average common shares outstanding:
Basic			61,340				61,313				61,342				61,347
Diluted			61,796				61,721				61,806				61,731
Percentage of net sales:
Net sales			100.0	%			100.0	%			100.0	%			100.0	%
Cost of sales			60.1				62.1				59.5				60.6
Gross profit			39.9				37.9				40.5				39.4
Selling, general and administrative expenses			25.8				25.2				27.1				26.5
Depreciation and amortization expenses			1.5				1.4				1.5				1.4
Pre-opening expenses			1.3				0.8				1.2				0.7
Operating income			11.3				10.5				10.6				10.8
Interest income, net			(0.7	)			(0.7	)			(0.7	)			(0.8	)
Income before income taxes			12.0				11.2				11.3				11.6
Income tax expense			3.0				2.7				2.7				2.8
Net income			9.0	%			8.5	%			8.7	%			8.8	%
Components may not add to totals due to rounding.

Ollie’s Bargain Outlet Holdings, Inc.

Condensed Consolidated Balance Sheets (unaudited)

(In thousands)

		August 2,				August 3,
Assets			2025				2024
Current assets:
Cash and cash equivalents		$	231,163			$	170,600
Short-term investments			85,893				182,544
Inventories			637,236				531,286
Accounts receivable			1,810				1,187
Prepaid expenses and other current assets			11,716				9,813
Total current assets			967,818				895,430
Property and equipment, net			360,836				307,163
Operating lease right-of-use assets			652,341				494,169
Goodwill			444,850				444,850
Trade name			230,559				230,559
Long-term investments			143,206				–
Other assets			2,242				2,122
Total assets		$	2,801,852			$	2,374,293
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt		$	518			$	589
Accounts payable			165,629				129,824
Income taxes payable			129				–
Current portion of operating lease liabilities			103,122				87,476
Accrued expenses and other current liabilities			98,968				79,952
Total current liabilities			368,366				297,841
Long-term debt			912				984
Deferred income taxes			85,640				72,803
Long-term portion of operating lease liabilities			561,024				411,994
Total liabilities			1,015,942				783,622
Stockholders’ equity:
Common stock			68				67
Additional paid-in capital			745,636				713,509
Retained earnings			1,476,583				1,263,275
Treasury – common stock			(436,377	)			(386,180	)
Total stockholders’ equity			1,785,910				1,590,671
Total liabilities and stockholders’ equity		$	2,801,852			$	2,374,293

Ollie’s Bargain Outlet Holdings, Inc.

Condensed Consolidated Statements of Cash Flows (unaudited)

(In thousands)

		Thirteen weeks ended								Twenty-six weeks ended
		August 2,				August 3,				August 2,				August 3,
			2025				2024				2025				2024
Net cash provided by operating activities		$	80,712			$	43,875			$	109,414			$	84,059
Net cash used in investing activities			(39,744	)			(90,883	)			(58,010	)			(159,398	)
Net cash (used in) provided by financing activities			(8,823	)			5,358				(25,364	)			(20,323	)
Net increase (decrease) in cash and cash equivalents			32,145				(41,650	)			26,040				(95,662	)
Cash and cash equivalents, beginning of the period			199,018				212,250				205,123				266,262
Cash and cash equivalents, end of the period		$	231,163			$	170,600			$	231,163			$	170,600

Ollie’s Bargain Outlet Holdings, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited)

(In thousands except for per share amounts)

		Thirteen weeks Ended								Twenty-six weeks ended
		August 2,				August 3,				August 2,				August 3,
			2025				2024				2025				2024
Net income		$	61,310			$	48,982			$	108,870			$	95,324
Excess tax benefits related to stock-based compensation(1)			(425	)			(756	)			(1,912	)			(1,888	)
Adjusted net income		$	60,885			$	48,226			$	106,958			$	93,436
Net income per diluted share		$	0.99			$	0.79			$	1.76			$	1.54
Adjustments as noted above, per dilutive share:
Excess tax benefits related to stock-based compensation(1)			(0.01	)			(0.01	)			(0.03	)			(0.03	)
Adjusted net income per diluted share		$	0.99			$	0.78			$	1.73			$	1.51
Diluted weighted-average common shares outstanding			61,796				61,721				61,806				61,731
Net income		$	61,310			$	48,982			$	108,870			$	95,324
Interest income, net			(4,534	)			(3,928	)			(9,322	)			(8,229	)
Depreciation and amortization expenses			13,452				10,039				26,261				19,824
Income tax expense			20,198				15,705				33,612				30,161
EBITDA			90,426				70,798				159,421				137,080
Non-cash stock-based compensation expense			3,360				3,652				6,524				6,801
Adjusted EBITDA		$	93,786			$	74,450			$	165,945			$	143,881
Components may not add to totals due to rounding.
(1)Amount represents the impact from the recognition of excess tax benefits pursuant to Accounting Standards Update 2016-09, Stock Compensation

Ollie’s Bargain Outlet Holdings, Inc.

Key Statistics (unaudited)

(Dollars in thousands)

		Thirteen weeks ended
		August 2,				August 3,
			2025				2024
Number of stores – beginning of period			584				516
Store openings			29				9
Store closings			–				–
Number of stores – end of period			613				525
Yr/yr store growth			16.8	%			8.9	%
Comparable stores sales change			5.0	%			5.8	%
Comparable store count – end of period			510				475
Total cash and investments(1)		$	460,262			$	353,144
Capital expenditures		$	26,416			$	38,289
Share repurchases		$	11,516			$	6,428
(1) Includes cash and cash equivalents, short-term investments, and long-term investments.

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor conferences in September.

Cantor Global Health Conference
Thursday, September 4, 2025
8:35 a.m. ET / 5:35 a.m. PT

H.C. Wainwright 27th Annual Global Investment Conference
Monday, September 8, 2025
1:00 p.m. ET / 10:00 a.m. PT

Morgan Stanley 23rd Annual Global Healthcare Conference
Wednesday, September 10, 2025
1:50 p.m. ET / 10:50 a.m. PT

Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following all three events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias and continues to pioneer advancements in both menin inhibition and farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Contacts

Investors and media:
Greg Mann
858-987-4046
[email protected]